Skip to main content
SpringerLink
Log in

Active Safety Surveillance in Africa: Pragmatism and Agility

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 07 April 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ndagije HB, Nambasa V, Manirakiza L, et al. The burden of adverse drug reactions due to artemisinin-based anti-malarial treatment in selected Ugandan health facilities–an active follow-up study. Drug Saf. 2018. https://doi.org/10.1007/s40264-018-0659-x.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449–60. https://doi.org/10.1586/17512433.2015.1053391.

    Article  CAS  Google Scholar 

  3. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689–703.

    Article  PubMed  Google Scholar 

  4. Ndomondo-Sigonda M, Miot J, Naidoo S, Dodoo A, Kaale E. Medicines regulation in Africa: current state and opportunities. Pharmaceut Med. 2017;31(6):383–97. https://doi.org/10.1007/s40290-017-0210-x.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Clemens J, Moorthy V. Implementation of RTS, S/AS01 malaria vaccine—the need for further evidence. N Engl J Med. 2016;374(26):2596–7. https://doi.org/10.1056/NEJMe1606007.

    Article  PubMed  Google Scholar 

  6. Suku CK, Hill G, Sabblah G, Darko M, Muthuri G, et al. Experiences and lessons from implementing cohort event monitoring programmes for antimalarials in four African countries: results of a questionnaire-based survey. Drug Saf. 2015;38(11):1115–26. https://doi.org/10.1007/s40264-015-0331-7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mssusa AK, Fimbo AM, Nkayamba AF, Irunde HF, Sillo HB, et al. Safety profile of artemether-lumefantrine: a cohort event monitoring study in public health facilities in Tanzania. Clin Drug Investig. 2016;36(5):401–11. https://doi.org/10.1007/s40261-016-0385-z.

    Article  PubMed  CAS  Google Scholar 

  8. Dodoo AN, Fogg C, Nartey ET, Ferreira GL, Adjei GO, et al. Profile of adverse events in patients receiving treatment for malaria in urban Ghana: a cohort-event monitoring study. Drug Saf. 2014;37(6):433–48. https://doi.org/10.1007/s40264-014-0164-9.

    Article  PubMed  CAS  Google Scholar 

  9. Bassi PU, Osakwe AI, Isah A, Suku C, Kalat M, et al. Safety of artemisinin-based combination therapies in Nigeria: a cohort event monitoring study. Drug Saf. 2013;36(9):747–56. https://doi.org/10.1007/s40264-013-0044-8.

    Article  PubMed  CAS  Google Scholar 

  10. Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai RA, et al. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J. 2016;27(15):43. https://doi.org/10.1186/s12936-016-1099-7.

    Article  CAS  Google Scholar 

  11. Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf. 2011;34(12):e1–9. https://doi.org/10.2165/11593830-000000000-00000.

    Article  PubMed  Google Scholar 

  12. Layton D, Shakir SA. Specialist cohort event monitoring studies: a new study method for risk management in pharmacovigilance. Drug Saf. 2015;38(2):153–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria—a double-center prospective study. J Infect Dis. 2014;209(12):1921–8.

    Article  PubMed  CAS  Google Scholar 

  14. Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39(4):335–45. https://doi.org/10.1007/s40264-015-0387-4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Kukula VA, Dodoo AA, Akpakli J, Narh-Bana SA, Clerk C, et al. Feasibility and cost of using mobile phones for capturing drug safety information in peri-urban settlement in Ghana: a prospective cohort study of patients with uncomplicated malaria. Malar J. 2015;19(14):411. https://doi.org/10.1186/s12936-015-0932-8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ghana Standards Authority, Accra, Ghana

    Alexander N. O. Dodoo

  2. African Collaborating Centre for Pharmacovigilance, Accra, Ghana

    Alexander N. O. Dodoo

Authors
  1. Alexander N. O. Dodoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander N. O. Dodoo.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this commentary.

Conflict of interest

Alexander N.O. Dodoo has no conflicts of interest directly relevant to the content of this commentary.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dodoo, A.N.O. Active Safety Surveillance in Africa: Pragmatism and Agility. Drug Saf 41, 731–733 (2018). https://doi.org/10.1007/s40264-018-0677-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-018-0677-8

Search

Navigation